Gordon Saxty

1.4k total citations
7 papers, 142 citations indexed

About

Gordon Saxty is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Gordon Saxty has authored 7 papers receiving a total of 142 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 2 papers in Organic Chemistry and 1 paper in Cellular and Molecular Neuroscience. Recurrent topics in Gordon Saxty's work include Fibroblast Growth Factor Research (3 papers), Click Chemistry and Applications (1 paper) and Chemical Synthesis and Analysis (1 paper). Gordon Saxty is often cited by papers focused on Fibroblast Growth Factor Research (3 papers), Click Chemistry and Applications (1 paper) and Chemical Synthesis and Analysis (1 paper). Gordon Saxty collaborates with scholars based in France, Belgium and Croatia. Gordon Saxty's co-authors include Thomas G. Davies, Valério Berdini, Marcel L. Verdonk, Paul G. Wyatt, Robin A. E. Carr, Steven J. Woodhead, Robert Downham, David Barford, Michelle D. Garrett and Robert G. Boyle and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and European Journal of Cancer.

In The Last Decade

Gordon Saxty

6 papers receiving 128 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gordon Saxty France 3 103 60 54 16 15 7 142
Mark Calmiano United Kingdom 5 67 0.7× 29 0.5× 45 0.8× 16 1.0× 8 0.5× 5 120
C. Hamlett United Kingdom 4 123 1.2× 28 0.5× 67 1.2× 15 0.9× 9 0.6× 5 188
Eric Nicolaï France 8 91 0.9× 36 0.6× 86 1.6× 10 0.6× 23 1.5× 18 190
Hendrik Falk Australia 7 135 1.3× 47 0.8× 56 1.0× 29 1.8× 16 1.1× 11 216
Ryan T. Koehler United States 9 150 1.5× 87 1.4× 28 0.5× 8 0.5× 10 0.7× 11 196
Briana Foley United States 9 127 1.2× 54 0.9× 49 0.9× 10 0.6× 9 0.6× 18 246
Divya Pingili India 6 169 1.6× 54 0.9× 114 2.1× 59 3.7× 25 1.7× 21 299
Shuqun Lin United States 8 76 0.7× 26 0.4× 95 1.8× 25 1.6× 31 2.1× 9 195
Bogdan Zagribelnyy Russia 4 124 1.2× 111 1.9× 38 0.7× 11 0.7× 17 1.1× 8 233
Huai Gao United States 6 82 0.8× 29 0.5× 64 1.2× 13 0.8× 4 0.3× 6 132

Countries citing papers authored by Gordon Saxty

Since Specialization
Citations

This map shows the geographic impact of Gordon Saxty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Saxty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Saxty more than expected).

Fields of papers citing papers by Gordon Saxty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Saxty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Saxty. The network helps show where Gordon Saxty may publish in the future.

Co-authorship network of co-authors of Gordon Saxty

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Saxty. A scholar is included among the top collaborators of Gordon Saxty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Saxty. Gordon Saxty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Southall, Stacey M., Joydeep Banerjee, Jason Brown, et al.. (2022). Novel Macrocyclic Antagonists of the CGRP Receptor Part 2: Stereochemical Inversion Induces an Unprecedented Binding Mode. ACS Medicinal Chemistry Letters. 13(11). 1776–1782. 1 indexed citations
2.
Alihodžić, Sulejman, et al.. (2018). Current Trends in Macrocyclic Drug Discovery and beyond -Ro5. Progress in medicinal chemistry. 57(1). 113–233. 20 indexed citations
3.
Querolle, Olivier, Patrick Angibaud, N. Esser, et al.. (2015). Abstract 3640: Discovery of quinazolinones as fibroblast growth factor receptor (FGFR1-4) kinase inhibitors. Cancer Research. 75(15_Supplement). 3640–3640. 1 indexed citations
4.
Perera, Timothy, Jorge Vialard, Tinne Verhulst, et al.. (2014). Abstract 1738: JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity for targeted therapy. Cancer Research. 74(19_Supplement). 1738–1738. 8 indexed citations
5.
Querolle, Olivier, Valério Berdini, Gordon Saxty, et al.. (2014). 356 Discovery of novel pyrido[2,3-b]pyrazine as fibroblast growth factor receptor (FGFR-1, 2, 3 & 4) kinase inhibitors with nanomolar affinity. European Journal of Cancer. 50. 115–115. 1 indexed citations
6.
Saxty, Gordon, Steven J. Woodhead, Valério Berdini, et al.. (2007). Identification of Inhibitors of Protein Kinase B Using Fragment-Based Lead Discovery. Journal of Medicinal Chemistry. 50(10). 2293–2296. 110 indexed citations
7.
Wyatt, Paul G., Valério Berdini, Maria G. Carr, et al.. (2004). 117 Identification of novel cyclin dependent kinase 1/2 inhibitors using fragment based high-throughput X-ray crystallography and structure based drug design. European Journal of Cancer Supplements. 2(8). 38–38. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026